Cardiovascular

Bayer gets European Approval for its Novel Anticoagulant

Bayer's novel anticoagulant Xarelto has been granted marketing authorization in Europe. by Pierre-Philippe Luyet, PhD , 03/10/2008

FDA approval for The Medicines Company's drug

The Medicines Company introduces its second drug to the market. by Pierre-Philippe Luyet, PhD , 07/08/2008

Readily available injections for irregular heart beats

Sagen Pharmaceuticals launched on the market its product Amiodarone HCl Injection.30/07/2008

CV Therapeutics gets European approval for Ranolazine

Ranolazine indicated for the treatment of chronic angina should arrive on the European market as soon as the beginning of 2009.18/07/2008


CardiovascularHeadlines




CardiovascularPartnerships
December 15th, 2009, AstraZeneca and the University of Virginia (UVa) in Charlottesville, announced that they had entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).
May 18th, 2009, Solvay Pharmaceuticals announced it had signed an agreement with HUYA Bioscience International.